Lixivaptan

Lixivaptan

Lixivaptan is a vasopressin receptor antagonist used in the treatment of hyponatremia (low blood sodium levels) associated with conditions like congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). It is developed by Cardiokine Inc., a biopharmaceutical company focused on the discovery and development of new treatments for cardiovascular diseases.

Mechanism of Action

Lixivaptan works by blocking the action of vasopressin, a hormone that regulates the body's water balance. It specifically targets the vasopressin V2 receptor, which is primarily found in the kidneys. By blocking this receptor, Lixivaptan increases the excretion of water in the urine, thereby increasing the concentration of sodium in the blood.

Clinical Trials

Lixivaptan has undergone several clinical trials to evaluate its safety and efficacy. In a Phase III clinical trial, Lixivaptan was shown to be effective in correcting hyponatremia in patients with heart failure and SIADH. However, the drug has not yet received approval from the Food and Drug Administration (FDA).

Side Effects

Common side effects of Lixivaptan include dry mouth, thirst, and increased urination. In some cases, it may also cause a rapid increase in blood sodium levels, which can lead to serious complications such as osmotic demyelination syndrome.

See Also

• Vasopressin receptor antagonist
• Hyponatremia
• Congestive heart failure
• Cirrhosis
• Syndrome of inappropriate antidiuretic hormone